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Model calibration yielded R0= 1.1. A coverage of 50 to 75% of the 2-17 years-old with 
QLAIV averted 295,400 to 374,000 symptomatic influenza cases/year (-45% to -57% 
of the current number of cases), of which 187,000 to 242,000 cases were among 
adults ≥ 18 (due to indirect effects). Vaccinating 75% of the 2-11 years-old and 50% 
of the 12-17 years-old averted 333,200 cases/year (of which 213,000 cases/year were 
in adults). Vaccinating only healthy 2-5 years-old or only increasing the coverage of 
at-risk 2-17 children generated direct protection but only limited indirect protec-
tion even with 90% coverage: respectively 72,500 (-11%) or 37,500 (-6%) total averted 
cases/year. Sensitivity analyses showed robustness of these results. ConClusions: 
The model demonstrates both direct and indirect protection benefits of vaccinating 
healthy children with QLAIV in Belgium. Policies targeting only at-risk individuals or 
the youngest provide limited herd protection as school-age children are important 
influenza vectors due to their high contact frequencies within the community.
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objeCtives: The Highly Active Antiretroviral Treatment(HAART) expense plays 
a crucial role in managing resources properly .Aim of this work is to validate a 
scoring system that combines appropriateness, drug-spending and clinical out-
comes. Methods: All patients followed by our HIV outpatients service who started 
a first or an early switch regimen(II line) in 2014 have been enrolled. Demographic 
and epidemiological data were recorded. Each HIV treatment receives a score result-
ing from combining its relevance (according to Italian guidelines) and its related 
monthly cost. The most appropriate and less expensive regimen got a score of 1 
point, whilst other are rated declining progressively by 0,05 points according to their 
value based on the two parameters described above (range: 1-0,1). Furthermore, 
we followed the clinical course recording CD4 cell increase and HIV viral load 
decrease as a surrogate marker of quality of life. Results: 42 pts. included (29 
male); mean age : 42 years. 26 patients were in first line, 13 on early switch, 3 in 
both lines. Average treatment duration was 198 days (16-362). Mean CD4 was 270 
cc/ml for 1st line patients and 462 for early switch respectively. 11 Only 9 patients 
were classified C according to CDC criteria (A= 11; B= 26). We obtained an overall 
appropriateness score of 0,89, tenofovir-Based Single Tablet Regimens (TVD-STR) 
rated 0,99 , PI-Based Regimens got a score of 0,91. Mean monthly therapy cost was 
€ 627,3 vs. € 719,8 respectively. After three months, all patients were virologically 
suppressed. ConClusions: Our study helped in defining the APROSCE system as 
an efficacious tool to evaluate the correlation of treatment appropriateness, drug 
expense and clinical outcomes .Higher score is a predictor of better outcomes and 
less drug expenditure. Related savings might be invested in more complex patients 
management with multi drug resistant strains or AIDS presenter.
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objeCtives: A number of treatment combinations are licensed for genotype 1 (GT1) 
hepatitis C (HCV)infection. A mixed treatment comparison (MTC) is a methodological 
tool that allows estimation of the relative effectiveness of interventions that have not 
been compared directly through phase III comparative randomised controlled trials 
(RCT). The aim of this study is to indirectly estimate the relative treatment effect of 
licensed regimens for the treatment of genotype-1, treatment naïve (TN) patients with 
chronic HCV infection. Methods: A systematic review identified relevant phase II and 
III studies. Studies that evaluated licensed interferon-containing and interferon-free 
regimens for GT1 chronic HCV were included. A MTC was undertaken for an overall 
cohort of GT1, TN patients, not stratified according to genotype 1a or 1b, or the pres-
ence or absence of cirrhosis. Results were obtained by using Markov chain Monte 
Carlo simulation in OpenBugs3.2.3. Results: Two hundred and forty nine studies 
were identified of whom thirty-five met the inclusion criteria. Eight treatments were 
compared in a MTC analysis, where single-agent studies were excluded. A cumula-
tive rankogram was constructed which illustrated that the probability of sofosbuvir/
daclatasvir (SOF/DCV) being the most effective treatment was 55%. This was fol-
lowed by sofosbuvir/ledipasvir (SOF/LDV) (37%) and paritaprevir, boosted with rito-
navir, in combination with ombitasvir and dasabuvir with ribavirin (P/rOD) (6.6%). 
Incorporating additional evidence from single-agent studies and matching them with 
data from similar arms of other studies allows for the inclusion of two additional regi-
mens; daclatasvir with pegylated-interferon and ribavirin (DCV/PR) and simeprevir/
sofosbuvir (SIM/SOF). ConClusions: In this MTC, SOF/DCV is the most effective 
treatment for genotype 1, TN hepatitis C patients. In the absence of head-to-head 
trials, MTCs play a crucial role in guiding clinical decision making. The analysis from 
this study will provide relevant information on licensed regimens for the hepatitis C 
infected, genotype 1, treatment naïve patients.
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objeCtives: Recommended treatment regimens for HIV-1-infected patients com-
bine antivirals from different therapeutic classes, usually a two-drug backbone (TDF/
FTC or ABC/3TC) with a third agent from another therapeutic class. We sought to 
understand the clinical evidence differentiating these backbones in treatment-naïve 
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objeCtives: To evaluate the virological outcomes of a cohort of HIV infected 
patients started on antiretroviral treatment (ART) and followed up for 10 years in 
Uganda. Methods: The study was performed at the Infectious Diseases Institute, 
Uganda. Viral load (VL) testing was performed every 6 months. We reported propor-
tion and cumulative probability (Kaplan Meier methods) of 1) achieving viral sup-
pression (VS) (at least one VL < 400 copies/ml) 2) experiencing viral failure in patients 
who achieved suppression, (2 consecutive VL > 1000 copies or one VL> 5,000 for those 
without a subsequent VL according to WHO guidelines) We used Cox regression 
methods to determine the characteristics associated with unfavorable virological 
outcomes (no suppression or viral failure). We included gender, baseline age, WHO-
stage, body max index (BMI), CD4 count, VL and time-dependent CD4-count and 
ART-adherence. Predictors with a P-value ≤ 0.2 in the unadjusted analysis were 
included in the multivariate analysis. Results: 472/559 (84.8%) patients had at 
least one VL (67 died, 14 lost, 4 transferred, 2 no VL available). 69% were female, 
median age was 44 years (IQR: 39-51), 89.9% were in WHO-stage 3&4, median CD4 
count was 102 cell/µL (IQR:31-167), median log10 VL 5.4 (IQR:5.1-5.8); 73.6% started 
on d4T/3TC/nevirapine and 26.4% on AZT/3TC/efavirenz. 439/472 (93%) achieved VS, 
cumulative probability: 94.1% (CI:91.7-96.1). 135/439 (30.7%) experienced VF, cumula-
tive probability: 33.9 %(CI: 29.4-38.9). In the multivariate analysis initial d4T/3TC/
nevirapine (HR:1.92, CI:1.28-2.87, P< 0.001) was associated with unfavorable viral 
outcomes while patients with adherence > 95% (HR:0.12, CI:0.05-0.27) and higher 
time-dependent CD4-count (HR:0.993 per 50 cell/µL increase, CI:0.94-0.99, P< 0.001) 
were less likely to obtain an unfavorable outcome. ConClusions: Achieving and 
maintaining viral suppression is associated with reduction in mortality and mor-
bidity and it is a key factor in the strategy of using ART as treatment as prevention: 
our results are encouraging and comparable to those from resource-rich settings.
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objeCtives: A comparison of all available once-daily fixed dose STR to MTR (of 
any frequency, containing FDC) using randomized controlled trials, observational 
studies and economic models focused on adherence measures could inform HIV 
healthcare providers and policy makers regarding modalities of patient disease man-
agement to improve health outcomes. A systematic review and meta-analysis of 
published literature was conducted to compare STR to MTR. Methods: Published 
literature in English between 2005 and 2014 was searched using Embase, Medline, 
PubMed (Medline in-process) and ClinicalTrial.Gov databases. Two-level screening 
was undertaken by two independent researchers to finalize articles for evidence 
synthesis. Adherence, efficacy, safety, tolerability, HRU and costs were assessed 
comparing STR to MTR. A random effects meta-analysis was performed and 
heterogeneity examined using meta-regression. Adherence, HRU/Cost evaluations 
are summarized in this abstract. Results: Of the 39 articles identified for qualitative 
evidence synthesis, 22 reported patient adherence outcomes and 5 had quantifiable 
data for meta-analysis. STR patients were statistically significantly more adher-
ent (per respective study-defined adherence goals) compared to MTR patients of 
any frequency (Odds Ratio (OR):2.37 (95% CI:1.68, 3.35) (p < 0.001)), twice-daily MTR 
(OR:2.53 (95% CI:1.13, 5.66) and once-daily MTR (OR:1.81 (1.15, 2.84)). Several stud-
ies reported significant reduction in HRU and costs among STR group versus MTR 
(albeit, none was eligible for meta-analysis): mean costs (annual, bi-annual, monthly 
or per-diem) were found to be lower for the STR group compared to MTR, and STR was 
also deemed cost-effective, based on its lower incremental cost-effectiveness ratio 
(ICER). ConClusions: STR demonstrated significant impact on improving adherence 
and potentially lowering overall HRU and costs in comparison to MTR. These find-
ings may have policy implications for HIV disease management in resource-limited 
settings, considering the known associations between ART adherence and improve-
ments in humanistic/clinical burden among HIV patients, and the potential HRU/
cost savings associated with STRs.
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objeCtives: To estimate the public health outcomes associated with vaccination of 
healthy Belgian children aged 2-17 years using an intranasal tetravalent live-attenu-
ated influenza vaccine (QLAIV), compared to the current coverage of at-risk/elderly 
individuals with the trivalent inactivated vaccine (TIV). Methods: A deterministic, 
age-structured, dynamic model was used to simulate influenza transmission (4 
strains) in the Belgian population, under the current coverage or after extending 
vaccination coverage to healthy children aged 2-17 with QLAIV. Differential equa-
tions describe demographic changes, exposure to infectious individuals (between-
individuals contact frequencies from the Belgian POLYMOD matrix), vaccination 
immunity dynamics, infection and recovery (parameters from international lit-
erature). The basic reproduction number (R0) was calibrated to the observation of 
285,951 influenza doctor visits/year (Belgian surveillance network). Efficacy was 
80% QLAIV vs. 59-68% TIV. The 10-year incidence of symptomatic influenza was 
calculated with different coverage scenarios (add-on to current coverage). Results: 
